Literature DB >> 16978025

Study of the sequence of events involved in nevirapine-induced skin rash in Brown Norway rats.

Marija Popovic1, Jeff L Caswell, Baskar Mannargudi, Jacintha M Shenton, Jack P Uetrecht.   

Abstract

Nevirapine, used for the treatment of HIV infection, is associated with development of skin rash and liver toxicity. The mechanism of these idiosyncratic reactions is unknown. We have previously reported the discovery of a new animal model of nevirapine-induced skin rash in rats. When treated with nevirapine, Brown Norway rats developed red ears on about day 7 and skin rash on about day 21. On rechallenge, ears turn red within 24 h, and skin lesions develop by day 9. In the current study, we analyzed the time course of the sequence of events involved in the development of skin rash. Rats were treated with nevirapine for 7, 14, or 21 days or rechallenged with it for 0, 1, or 9 days. This treatment led to an increase in the total number of auricular lymph node T, B, and macrophage cells. There was also an increase in the activation/infiltration marker ICAM-1 and activation/antigen presentation marker MHC II in these cells compared with those from control rats. Immunohistochemistry analysis showed macrophage infiltration and ICAM-1 expression in the ears of treated rats as early as day 7 of treatment. Macrophage infiltration preceded T cell infiltration, which was not apparent until the onset of rash. Both MHC I and MHC II expression increased in the skin of nevirapine-treated rats that developed rash. A major inducer of MHC is IFNgamma. Although rechallenge with nevirapine led to a large increase in serum levels of IFNgamma, this was not observed during the treatment of naïve rats with nevirapine. These observations provide further clues to the mechanism of nevirapine-induced skin rash.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16978025     DOI: 10.1021/tx0601152

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  6 in total

1.  Protein adducts as prospective biomarkers of nevirapine toxicity.

Authors:  Alexandra M M Antunes; Ana L A Godinho; Inês L Martins; M Conceição Oliveira; Ricardo A Gomes; Ana V Coelho; Frederick A Beland; M Matilde Marques
Journal:  Chem Res Toxicol       Date:  2010-09-01       Impact factor: 3.739

2.  The Association of HLA-B*35 and GSTT1 Genotypes and Hepatotoxicity in Thai People Living with HIV.

Authors:  Noppadol Chanhom; Jiraphun Jittikoon; Sukanya Wattanapokayakit; Surakameth Mahasirimongkol; Angkana Charoenyingwattana; Wanvisa Udomsinprasert; Usa Chaikledkaew; Supharat Suvichapanich; Taisei Mushiroda; Sasisopin Kiertiburanakul; Archawin Rojanawiwat; Wittaya Wangsomboonsiri; Weerawat Manosuthi; Pacharee Kantipong; Anucha Apisarnthanarak; Wilawan Sangsirinakakul; Pawinee Wongprasit; Romanee Chaiwarith; Woraphot Tantisiriwat; Somnuek Sungkanuparph; Wasun Chantratita
Journal:  J Pers Med       Date:  2022-06-08

3.  Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries.

Authors:  Abhishek Srivastava; Lu-Yun Lian; James L Maggs; Masautso Chaponda; Munir Pirmohamed; Dominic P Williams; B Kevin Park
Journal:  Drug Metab Dispos       Date:  2010-01       Impact factor: 3.922

4.  2'-Deoxythymidine adducts from the anti-HIV drug nevirapine.

Authors:  Alexandra M M Antunes; Benjamin Wolf; M Conceição Oliveira; Frederick A Beland; M Matilde Marques
Journal:  Molecules       Date:  2013-04-26       Impact factor: 4.411

5.  The role of the immune system in nevirapine-induced subclinical liver injury of a rat model.

Authors:  Zanelle Bekker; Andrew Walubo; Jan B du Plessis
Journal:  ISRN Pharm       Date:  2012-08-16

6.  Drug reaction with eosinophilia and systemic symptoms related to antiretroviral treatment in human immunodeficiency virus patients.

Authors:  David Brandariz; Alex Smithson; Vanesa Anton-Vazquez
Journal:  Indian J Sex Transm Dis AIDS       Date:  2017 Jul-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.